CORCEPT THERAPEUTICS INC (CORT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $142.00K; Additional Paid in Capital, Common StockUSD $1.05B; Additional Paid in CapitalUSD (m).
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD $1.00B; Additional Paid in CapitalUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $140.00K; Additional Paid in Capital, Common StockUSD $968.60M; Additional Paid in CapitalUSD (m).
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $139.00K; Additional Paid in Capital, Common StockUSD $933.61M; Additional Paid in CapitalUSD (m).
CORCEPT THERAPEUTICS INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Outstanding USD | Common Stock, Value, Outstanding USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Value USD | Treasury Stock, Value, Acquired, Cost Method USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Treasury Stock, Shares, Acquired shares | Treasury Stock Acquired, Average Cost Per Share USD/shares | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $142.00K | $1.05B | (m) | $998.01M | $436.00K | $654.61M | $705.78M | (m) | (m) | (m) | 3 month · $2.73M | 3 month · $24.47M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $1.00B | (m) | $976.69M | $918.00K | $611.63M | $637.99M | $0.00 | $141.00K | (m) | 3 month · $815.00K | 3 month · $21.71M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $140.00K | $968.60M | (m) | $966.59M | $2.26M | $643.39M | $647.80M | $0.00 | $140.00K | 36.55M | 12 month · $9.94M | 12 month · $76.51M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $139.00K | $933.61M | (m) | $923.29M | $2.34M | $619.10M | $631.90M | (m) | (m) | (m) | 3 month · $2.42M | 3 month · $20.39M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $138.00K | $900.86M | (m) | $866.93M | $2.29M | $599.43M | $635.79M | (m) | (m) | (m) | 3 month · $3.45M | 3 month · $19.43M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $862.87M | (m) | $744.69M | $692.00K | $564.28M | $683.28M | $0.00 | $137.00K | (m) | 3 month · $2.17M | 3 month · $15.69M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $136.00K | $832.11M | $832.11M | $696.17M | $-217.00K | $543.74M | $679.59M | $0.00 | $136.00K | 32.64M | 12 month · $5.04M | 12 month · $55.71M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $135.00K | $806.32M | (m) | $682.18M | $1.57M | $512.99M | $638.84M | (m) | (m) | (m) | 3 month · $698.00K | 3 month · $14.29M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $134.00K | $781.01M | (m) | $650.76M | $84.00K | $465.78M | $596.24M | (m) | (m) | (m) | 3 month · $1.31M | 3 month · $13.88M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $758.24M | (m) | $641.06M | $258.00K | $430.29M | $547.86M | $0.00 | $133.00K | (m) | 3 month · $1.28M | 3 month · $12.93M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $133.00K | $738.51M | $738.51M | $635.08M | $609.00K | $402.53M | $506.70M | $0.00 | $133.00K | 30.94M | 12 month · $1.07M | 12 month · $45.98M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $133.00K | $722.40M | (m) | $631.79M | $-234.00K | $371.17M | $461.68M | (m) | (m) | (m) | 3 month · $1.07M | 3 month · $11.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $132.00K | $695.72M | (m) | $614.07M | $45.00K | $339.79M | $421.61M | (m) | (m) | (m) | (m) | 3 month · $11.37M | (m) | 3 month · $145.43M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $131.00K | $679.85M | (m) | $462.51M | $-153.00K | $312.26M | $529.58M | (m) | (m) | (m) | (m) | 3 month · $10.97M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $131.00K | $662.34M | $662.34M | $456.15M | $-869.00K | $296.39M | $501.84M | $0.00 | $131.00K | 23.12M | (m) | 12 month · $42.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $130.00K | $648.83M | (m) | $453.00M | $-2.38M | $279.79M | $473.36M | (m) | (m) | (m) | (m) | 3 month · $10.63M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $128.00K | $625.98M | (m) | $426.81M | $-2.14M | $245.18M | $442.33M | (m) | (m) | (m) | (m) | 3 month · $10.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $128.00K | $608.72M | (m) | $417.45M | $-1.35M | $217.76M | $407.81M | (m) | (m) | (m) | (m) | 3 month · $10.82M | (m) | (m) | (m) | 3 month · 21.60M | (m) | (m) |
| 2021-12-31 | $0.00 | $127.00K | $591.35M | $591.35M | $410.41M | $-227.00K | $194.97M | $375.81M | (m) | (m) | 21.28M | (m) | 12 month · $43.17M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $0.00 | $126.00K | $571.38M | (m) | $194.30M | $115.00K | $162.91M | $540.23M | (m) | (m) | (m) | (m) | 3 month · $11.00M | (m) | 3 month · $25.77M | (m) | 9 month · 4.30M | 9 month · 22.69 | 10.90M |
| 2021-06-30 | $0.00 | $125.00K | $554.15M | (m) | $164.26M | $215.00K | $132.44M | $522.67M | (m) | (m) | (m) | (m) | 3 month · $11.13M | (m) | 3 month · $29.17M | (m) | (m) | (m) | 9.50M |
| 2021-03-31 | $0.00 | $124.00K | $536.36M | (m) | $131.85M | $249.00K | $105.92M | $510.80M | (m) | (m) | (m) | (m) | 3 month · $10.14M | (m) | 3 month · $33.54M | (m) | 3 month · 21.30M | (m) | (m) |
| 2020-12-31 | $0.00 | $122.00K | $516.14M | $516.14M | $75.80M | $415.00K | $82.46M | $523.34M | (m) | (m) | 5.85M | (m) | (m) | (m) | 12 month · $9.95M | (m) | (m) | (m) | 5.30M |
| 2020-09-30 | $0.00 | $121.00K | $496.49M | (m) | $63.97M | $577.00K | $56.46M | $489.68M | (m) | (m) | (m) | (m) | 3 month · $8.76M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $121.00K | $481.71M | (m) | $63.81M | $840.00K | $34.84M | $453.70M | (m) | (m) | (m) | (m) | 3 month · $8.55M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $0.00 | $120.00K | $465.53M | (m) | $62.98M | $310.00K | $6.51M | $409.49M | (m) | (m) | (m) | (m) | 3 month · $7.99M | (m) | 3 month · $275.00K | (m) | 3 month · 5.20M | (m) | (m) |
| 2019-12-31 | $0.00 | $120.00K | $457.06M | $457.06M | $62.70M | $261.00K | $-23.55M | $371.18M | (m) | (m) | 5.22M | (m) | (m) | (m) | 12 month · $30.98M | (m) | (m) | (m) | (m) |
| 2019-09-30 | $0.00 | $119.00K | $446.61M | (m) | $59.73M | $314.00K | $-52.94M | $334.38M | (m) | (m) | (m) | (m) | 3 month · $7.29M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $0.00 | $118.00K | $436.62M | (m) | $59.73M | $321.00K | $-79.28M | $298.05M | (m) | (m) | (m) | (m) | 3 month · $7.79M | (m) | 3 month · $17.42M | (m) | (m) | (m) | (m) |
| 2019-03-31 | $0.00 | $118.00K | $427.32M | (m) | $42.31M | $94.00K | $-99.46M | $285.75M | (m) | (m) | (m) | (m) | 3 month · $6.72M | (m) | 3 month · $13.55M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $117.00K | $417.23M | $417.23M | $23.66M | $-70.00K | $-117.74M | $275.88M | (m) | (m) | 1.81M | (m) | (m) | $23.66M | 12 month · $23.66M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $116.00K | $408.15M | (m) | $8.90M | $-77.00K | $-139.74M | $259.55M | (m) | (m) | (m) | (m) | 3 month · $6.51M | (m) | 3 month · $8.90M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $116.00K | $401.01M | (m) | (m) | $-127.00K | $-157.49M | $243.51M | (m) | (m) | (m) | (m) | 3 month · $6.02M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $115.00K | $390.95M | (m) | (m) | $-152.00K | $-175.69M | $215.23M | (m) | (m) | (m) | (m) | 3 month · $4.95M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $115.00K | $384.07M | $384.07M | (m) | $-75.00K | $-193.15M | $190.97M | (m) | (m) | 0.00 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $114.00K | (m) | $377.68M | (m) | $-14.00K | $-291.48M | $86.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $113.00K | (m) | $371.28M | (m) | $-17.00K | $-305.23M | $66.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $113.00K | (m) | $367.36M | (m) | $-12.00K | $-317.88M | $49.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $113.00K | (m) | $363.53M | (m) | $0.00 | $-322.27M | $41.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $111.00K | (m) | $358.00M | (m) | (m) | $-326.87M | $31.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $110.00K | (m) | $355.00M | (m) | (m) | $-329.45M | $25.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $110.00K | (m) | $350.49M | (m) | (m) | $-330.43M | $20.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $110.00K | (m) | $348.80M | (m) | (m) | $-330.41M | $18.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $109.00K | (m) | $344.74M | (m) | (m) | $-331.37M | $13.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $108.00K | (m) | $342.18M | (m) | (m) | $-330.77M | $11.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $108.00K | (m) | $339.29M | (m) | (m) | $-328.83M | $10.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $101.00K | (m) | $320.51M | (m) | (m) | $-324.00M | $-3.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $101.00K | (m) | $318.69M | (m) | (m) | $-320.11M | $-1.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $0.00 | $101.00K | (m) | $317.45M | (m) | (m) | $-314.10M | $3.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $101.00K | (m) | $315.82M | (m) | (m) | $-306.55M | $9.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | $100.00K | (m) | $313.53M | (m) | (m) | $-292.62M | $21.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $100.00K | (m) | $312.17M | (m) | (m) | $-281.49M | $30.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $100.00K | (m) | $310.86M | (m) | (m) | $-270.59M | $40.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $100.00K | (m) | $309.59M | (m) | (m) | $-258.69M | $51.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $100.00K | (m) | $308.28M | (m) | (m) | $-246.61M | $61.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $100.00K | (m) | $307.03M | (m) | (m) | (m) | $71.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $89.00K | (m) | $259.90M | (m) | (m) | (m) | $32.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $89.00K | (m) | $258.82M | (m) | (m) | $-219.59M | $39.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $84.00K | (m) | $243.28M | (m) | (m) | $-208.56M | $34.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $3.07M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $84.00K | (m) | $242.21M | (m) | (m) | $-198.62M | $43.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $84.00K | (m) | $240.97M | (m) | (m) | $-192.19M | $48.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $72.00K | (m) | $197.47M | (m) | (m) | $-176.20M | $21.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $22.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $26.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2004-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $45.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2003-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-31.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2002-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-21.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2001-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-7.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2000-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-2.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 1999-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-244.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |